Waldenström’s Macroglobulinemia
- 8 January 2014
- book chapter
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemiaCancer, 2011
- Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaBritish Journal of Haematology, 2011
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's MacroglobulinemiaClinical Cancer Research, 2010
- Neurological manifestations of Waldenström macroglobulinemiaNature Clinical Practice Neurology, 2008
- Hepatitis C viral infection is not associated with Waldenström's macroglobulinemiaAmerican Journal of Hematology, 2006
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Case 3-1990The New England Journal of Medicine, 1990
- Biologic Activity of Cold-Reacting AutoantibodiesThe New England Journal of Medicine, 1977
- Biologic Activity of Cold-Reacting AutoantibodiesThe New England Journal of Medicine, 1977
- Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?Acta Medica Scandinavica, 1944